Document Type : Original Research


1 Department of Pathology, Chittagong Medical College, Chattogram, Bangladesh

2 Chattogram Ma O shishu Medical College, Chattogram, Bangladesh


Background & Objective: p16 is a tumor suppressor gene, loss of which is usually associated with poor epithelial differentiation, resulting in tumor progression, which correlates with aggressive clinical behavior and poor prognosis. CDK 4/6 inhibitors can be used as a therapeutic target in p16 negative cases. Bladder cancer is one of the most prevalent cancers, prognosis of which depends not only upon the histopathological type, grade, and invasiveness but also on many other factors. The purpose of this study was to examine p16 expression in bladder urothelial carcinoma among the people who receive treatment at a tertiary care facility in Chattogram, Bangladesh.
Methods: At the Department of Pathology, Chittagong Medical College we did this cross-sectional study from July 2019 to September 2021. The study included fifty-one cases of primary urothelial bladder cancer for histopathological examinations. Immunostaining was done by using a primary antibody against p16.
Results: Among the 51 cases, twenty-six cases (51%) showed positive p16 expression. The proportion of patients with high-grade (66.7%) and muscle-invasive (86.4%) tumors were more prone to show p16 negativity.
Conclusion: The result of this study shows the high grade and muscle-invasive urothelial bladder cancer is linked to reduction of p16 expression, which may provide additional prognostic information to stratify the high-risk patients and can also guide treatment plans, being a therapeutic target.


Main Subjects

  1. Chinnasamy R, Krishnamoorthy S, Joseph L, Kumaresan N, Ramanan V. Clinico-pathological study of bladder cancer in a tertiary care center of South India and Impact of age, gender, and tobacco in causing bladder cancer: a single center experience. International Journal of Scientific Study. 2016;3(10):72-7.
  2. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat Rev Dis Primers. 2017 Apr 13;3(1):17022. [DOI:10.1038/nrdp.2017.22] [PMID]
  3. Cumberbatch MGK, Cox A, Teare D, Catto JWF. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015 Dec 1;1(9):1282. [DOI:10.1001/jamaoncol.2015.3209] [PMID]
  4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017: Colorectal Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):177-93. [DOI:10.3322/caac.21395] [PMID]
  5. Hussain SMA. Comprehensive update on cancer scenario of Bangladesh. South Asian J Cancer. 2013 Oct;02(04):279-84. [DOI:10.4103/2278-330X.119901] [PMID] [PMCID]
  6. Michaeli JC, Boch T, Albers S, Michaeli T, Michaeli DT. Socio-economic burden of disease: Survivorship costs for bladder cancer. J Cancer Policy. 2022;32:100326.7. [DOI:10.1016/j.jcpo.2022.100326] [PMID]
  7. Balci MG, Tayfur M. Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder. Int J Clin Exp Pathol. 2018;11(8):4163-8.
  8. Tse J, Ghandour R, Singla N, Lotan Y. Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. Int J Molecul Sci. 2019;20(4):793. [DOI:10.3390/ijms20040793] [PMID] [PMCID]
  9. Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J Cancer. 2019;10(17):4038. [DOI:10.7150/jca.28989] [PMID] [PMCID]
  10. Tambunan MP, Saraswati M, Umbas R, Mochtar CA, Hamid AR. E-cadherin expressions on bladder and its association with cancer progressivity: a retrospective cohort study. Afr J Urol. 2022;28(1):14. (2022) 28:14. [DOI:10.1186/s12301-022-00280-z]
  11. Yang CH, Wu CC, Chen WT, Chai CY, Yang SF. Expressions of p16 and p27 in urothelial carcinoma and their prognostic value. Kaohsiung J Med Sci. 2014;30(9):453-8. [DOI:10.1016/j.kjms.2014.05.003] [PMID]
  12. Sirousbakht S, Rezakhaniha B. Effect of colonoscopy on prostate-specific antigen; new words about an old subject. Int J Cancer Manag. 2018;11(7). [DOI:10.1002/cyto.b.21487] [PMID]
  13. Kouzegaran S, Siroosbakht S, Farsad BF, Rezakhaniha B, Dormanesh B, Behnod V, Tanha AS. Elevated IL‐17A and IL‐22 regulate expression of inducible CD38 and Zap‐70 in chronic lymphocytic leukemia. Cytometry Part B: Clin Cytometr. 2018;94(1):143-7. [DOI:10.1002/cyto.b.21487] [PMID]
  14. Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL. p16(INK4a) expression in urinary bladder carcinoma. Arch Ital Urol Androl. 2006 Sep;78(3):97-100.
  15. Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2018;4(4):250-61. [DOI:10.1002/cjp2.109] [PMID] [PMCID]
  16. Nakazawa K, Murata S ichi, Yuminamochi T, Ishii Y, Ohno S, Nakazawa T, et al. p16INK4a Expression Analysis as an Ancillary Tool for Cytologic Diagnosis of Urothelial Carcinoma. Am J Clin Pathol. 2009 Nov 1;132(5):776-84. [DOI:10.1309/AJCP61KNVHJVHAFN] [PMID]
  17. Gan X, Lin X, He R, Lin X, Wang H, Yan L, et al. Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis. Dis Markers. 2016;2016:1-13. [DOI:10.1155/2016/5259602] [PMID] [PMCID]
  18. Sathe A, Koshy N, Schmid SC, Thalgott M, Schwarzenböck SM, Krause BJ, et al. CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1. J Urol. 2016;195(3):771-9. [DOI:10.1016/j.juro.2015.08.082] [PMID]
  19. Colombel M, Soloway M, Akaza H, Böhle A, Palou J, Buckley R, et al. Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. Eur Urol Suppl. 2008;7(10):618-26. [DOI:10.1016/j.eursup.2008.08.002]
  20. Han CP, Kok LF, Wang PH, Wu TS, Tyan YS, Cheng YW, et al. Scoring of p16INK4a immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol. 2009;22(6):797-806. [DOI:10.1038/modpathol.2009.31] [PMID]
  21. Zhao N, Ang MK, Yin XY, Patel MR, Fritchie K, Thorne L, et al. Different cellular p16INK4a localisation may signal different survival outcomes in head and neck cancer. Br J Cancer. 2012;107(3):482-90. [DOI:10.1038/bjc.2012.264] [PMID] [PMCID]
  22. Ahmed B, Shiraji KH, Chowdhury MHK, Uddin MG, Islam SN, Hossain S. Socio-economic Status of the Patients with Acute Coronary Syndrome: Data from a District-level General Hospital of Bangladesh. Cardiovasc J. 2017;10(1):17-20. [DOI:10.3329/cardio.v10i1.34357]
  23. Haque S, Dewan RK, Saleh S, Jennah SA, Jahan F, Akter F, Sultana T, Ferdaus NJ. Histomorphological study of urinary bladder tumor and status of HER2/Neu and Ki67 expression in urothelial carcinoma. J Histopathol Cytopathol. 2018;2(2):99-108.
  24. Chou YH, Chang WC, Wu WJ, Li CC, Yeh HC, Hou MF, et al. The association between gender and outcome of patients with upper tract urothelial cancer. The Kaohsiung Journal of Medical Sciences. 2013 Jan;29(1):37-42. [DOI:10.1016/j.kjms.2012.08.006] [PMID]
  25. Sadaf A, Rahman MZ, Bhattacharjee P, Ahamad MSU, Nasreen S. Significance of Vascular Endothelial Growth Factor Expression in the Bladder Urothelial Carcinoma and Its Association with Tumor Grade and Invasiveness. Iran J Pathol. 2021;16(4):362-9. [DOI:10.30699/ijp.2021.138671.2518] [PMID] [PMCID]
  26. Thapa R, Lakhey M, Bhatta A. Spectrum of histomorphological diagnosis in cystoscopic bladder biopsies. J Pathol Nep. 2017;7(1):1062-5. [DOI:10.3126/jpn.v7i1.16913]
  27. Lee K, Jung ES, Choi YJ, Lee KY, Lee A. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci. 2010;25(10):1449-55. [DOI:10.3346/jkms.2010.25.10.1449] [PMID] [PMCID]
  28. Hashmi AA, Hussain ZF, Irfan M, Hashmi SK, Asif H, Faridi N. Prognostic significance of p16 immunohistochemical expression in urothelial carcinoma. Surg Exp Pathol. 2019;2(1):3. [DOI:10.1186/s42047-019-0030-2]
  29. Alshaikhly AW, Kareem NM, Musa ZA. Papillary Urothelial Carcinoma of Urinary Bladder: A Comparative Study of The Immunohistochemical Staining Pattern of (Cytokeratin 20 and P16) And Its Relation to Tumor Grade and Other Factors. Int J Med Res Prof. 2017; 3(5): 41-47. [DOI:10.21276/ijmrp]
  30. Kumar VP, Yalavarthi S, Rukmangadha N. Correlation of P53 status with histological grading of urinary Bladder Transitional cell carcinoma. Scholars Journal of Applied Medical Sciences. 2017;5(1D) :286-291.
  31. Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol. 2009 Apr;25(2):207-10. [DOI:10.4103/0970-1591.52916] [PMID] [PMCID]
  32. Rushton L, Bagga S, Bevan R, Brown TP, Cherrie JW, Holmes P, et al. Occupation and cancer in Britain. Br J Cancer. 2010;102(9):1428-37. [DOI:10.1038/sj.bjc.6605637] [PMID] [PMCID]